Kenvue Inc. (NYSE:KVUE) Shares Acquired by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D grew its holdings in Kenvue Inc. (NYSE:KVUE) by 10.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 966,624 shares of the company’s stock after purchasing an additional 93,478 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Kenvue were worth $20,811,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of KVUE. Empirical Finance LLC acquired a new position in Kenvue during the 3rd quarter worth about $336,000. UniSuper Management Pty Ltd purchased a new stake in Kenvue during the 3rd quarter worth about $35,544,000. Citizens Business Bank purchased a new stake in Kenvue during the 3rd quarter worth about $2,507,000. Fifth Third Bancorp increased its holdings in Kenvue by 35.3% during the 4th quarter. Fifth Third Bancorp now owns 277,580 shares of the company’s stock worth $5,976,000 after purchasing an additional 72,435 shares during the period. Finally, Clearbridge Investments LLC increased its holdings in Kenvue by 364.6% during the 3rd quarter. Clearbridge Investments LLC now owns 484,321 shares of the company’s stock worth $9,725,000 after purchasing an additional 380,071 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Price Performance

KVUE stock traded down $0.11 during midday trading on Thursday, hitting $19.02. 14,246,216 shares of the stock were exchanged, compared to its average volume of 16,707,334. The stock’s 50-day moving average price is $19.84 and its 200-day moving average price is $20.15. Kenvue Inc. has a fifty-two week low of $17.82 and a fifty-two week high of $27.80. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.78 and a current ratio of 1.12.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, February 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.03. The firm had revenue of $3.67 billion during the quarter, compared to analysts’ expectations of $3.78 billion. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The firm’s quarterly revenue was down 2.7% on a year-over-year basis. As a group, research analysts forecast that Kenvue Inc. will post 1.15 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently commented on KVUE. JPMorgan Chase & Co. dropped their price objective on Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday, February 9th. Royal Bank of Canada dropped their price target on Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research note on Friday, February 9th. Sanford C. Bernstein started coverage on Kenvue in a research note on Thursday, April 11th. They set an “underperform” rating and a $18.00 price target on the stock. The Goldman Sachs Group started coverage on Kenvue in a research report on Friday, March 1st. They set a “neutral” rating and a $20.00 price objective for the company. Finally, William Blair started coverage on Kenvue in a research report on Wednesday, April 3rd. They set a “market perform” rating for the company. One analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $24.85.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.